Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 9

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 9
---
 “Use of Proceeds” on page S-12.                                                                                                                                                                    |

| Risk Factors | Investing in our common stock involves significant risks. You should read the “Risk Factors” on page S-9 of this prospectus supplement and in the documents incorporated by 
 reference in this prospectus supplement for a discussion of factors to consider before deciding to purchase shares of our common stock.                                     |

| Nasdaq Capital Market symbol | “WHWK” |

The number of shares of common stock to be outstanding after this offering is based on 24,680,708 shares of common stock outstanding as of December 31, 2024 and excludes, in each case as of December 31, 2024:

| ∎ |     | 2,830,913 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were 
 outstanding as of December 31, 2024, with a weighted average exercise price of $13.82 per share;                    |

| ∎ |     | 2,426,493 shares of our common stock issuable upon the exercise of prefunded warrants to purchase common stock that 
 were outstanding as of December 31, 2024, with an exercise price of $12.4999 per share;                             |

| ∎ |     | 1,013,055 shares of common stock reserved for issuance pursuant to future awards under our 2021 Equity Incentive Plan,           
 as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and |

S-7

| ∎ |     | 810,743 shares of common stock reserved for issuance pursuant to future awards under our 2021 Employee Stock Purchase Plan,  
 as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan. |

In addition, unless we specifically state otherwise, all information in this prospectus assumes no exercise of outstanding stock options subsequent to December 31, 2024.

S-8

RISK FACTORS

You should consider carefully the risks described below and discussed under the section captioned “Risk Factors” contained in our most recent annual report on Form 10-Kas updated by our subsequent filings under the Exchange Act each of which is incorporated by reference in this prospectus supplement in their entirety, together with other information in this prospectus supplement, and the information and documents incorporated by reference in this prospectus supplement, and any free writing prospectus that we have authorized